HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology

×

Fehlermeldung

  • Notice: Undefined property: stdClass::$ds_changed in eval() (Zeile 16 von /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (Zeile 20 von /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (Zeile 20 von /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (Zeile 16 von /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (Zeile 20 von /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (Zeile 20 von /var/www/7/modules/php/php.module(80) : eval()'d code).

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Donnerstag, Januar 6, 2022
Information
Tags: 
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, NASH, Therapy, University, Fatty liver disease, Chronic liver disease, Roy Taylor (scientist), Lists of diseases, Patient, Primary biliary cholangitis, IND, T2DM, Chen Jin, Pharmacology, Buffalo, NAFLD, PSC, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Degenerative disease, SVP, Institute of Liver and Biliary Sciences, Drug, Clinical pharmacology, Amgen, State, Primary sclerosing cholangitis, HighTide, State university system, PBC, NDA, Pharmaceutical industry, Novartis
Geotags: 
MARYLAND, NEW YORK
⚠ generated by AI ↴
Organisation: 
HIGHTIDE THERAPEUTICS
Zusammenfassung
Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.
  • Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development.
  • Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases.
  • We are very pleased to welcome Jin to the HighTide team, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.


HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology. Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development. Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases. Dr. Chen will report to Dr. Leigh MacConell, Chief Development Officer of HighTide.

“We are very pleased to welcome Jin to the HighTide team,” said Liping Liu, Ph.D., Chief Executive Officer of HighTide. “Her expertise in clinical pharmacology and familiarity with our indications of interest are an excellent fit for HighTide’s global efforts to develop HTD1801 and expand our pipeline for patients with unmet needs.”

Prior to joining HighTide, Dr. Chen served various roles at Novartis from 2006-2021, including Clinical Development Director and Director, Clinical Pharmacology where she contributed to multiple IND submissions and an NDA submission and approval. Prior to Novartis, Dr. Chen served as Clinical PK Scientist at Amgen. Dr. Chen earned a Ph.D. in pharmaceutical sciences from the University at Buffalo, the State University of New York.

About HighTide Therapeutics

HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The lead drug candidate, HTD1801, is a first-in-class new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), nonalcoholic steatohepatitis comorbid with type 2 diabetes mellitus (NASH + T2DM), T2DM comorbid with nonalcoholic fatty liver disease (T2DM + NAFLD), etc.

For additional information, please visit https://hightidetx.com.

Copyright: 
Copyright Business Wire 2022